Household Transmission Dynamics of Multidrug Resistant Enterobacterales

NCT ID: NCT05798364

Last Updated: 2024-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

507 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-19

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The HOME study will prospectively follow a cohort of Multi-Drug Resistant Enterobacterales (MDR-E) carriers after hospital discharge, and their related household members over a 3-month period. The main objective is to estimate the rate of confirmed transmissions of MDR-E from the index cases to related household members, and identify predictors associated with transmission. Transmission will be confirmed by comparing genomic analysis of the MDR-E strains isolated both in the index patient and his/her household members, based on the number of Single nucleotide polymorphisms (SNPs) differences between nearby genomes by Variant Calling. Multifactorial processes involved in MDR-E transmission in households will be explored with stochastic individual-based modelling. The parameterized model will be used to simulate and assess different strategies of control of MDR-E emergence and transmission to households. The impact of modifying patterns of human-contacts, promote hygiene and control barriers (decontamination of objects or surfaces, variations in antibiotic use, reinforcement of hand hygiene) will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multi-Drug Resistant Enterobacterales (MDR-E), i.e. Extended-Spectrum Beta-Lactamase producing Enterobacterales (ESBL-E) and Carbapenemase-Producing Enterobacterales (CPE) are spreading worldwide. Although initially considered a healthcare-associated problem, reports of ESBL-E carriage and infections in individuals without any previous exposure to health care raise concerns on their alarming dissemination in the community. Very few reports investigated the dynamics of transmission of MDR-E from carriers to household members. Risk factors of acquisition (related to the strain, household habits, travel, occupational activities…) were poorly assessed.

Quantifying and understanding the mechanisms of household transmission is of major importance to elaborate control strategies specifically designed to the community.

The main objective is to estimate the rate of confirmed transmissions of MDR-E from an index case to related household members.

The primary endpoint is defined by the secondary attack rate (SAR) for confirmed transmissions, i.e. the proportion of confirmed (based on genetic analysis of strains) acquisitions of MDR-E in all household members over the study period (three months).

Screening of eligible patients will rely on an automated daily request of all MDR-E positive samples that is already implemented in the participating centers.

Information on the study will be given to eligible patients, those who meet eligibility criteria and willing to participate will be asked to ive non-opposition.

Seven days before hospital discharge, index patients who consent to participate will provide a fecal sample to be screened for MDR-E carriage. If the patient is still positive at discharge for MDR-E fecal carriage, he/she will be included in the cohort (=index case). His/her household members (=HH members) will then be invited to participate and included after agreement.

After inclusion, index cases and household members will be prospectively followed-up for 3 months (+/-7 days), and asked to provide self-collected stool samples and questionnaires on day7, day15, day21, day30, month2 and month3.

Self-collected stool samples will be mailed to the reference microbiology laboratory (Bichat) with self-filled questionnaires.

In addition, in the context of the ancillary study:

To obtain accurate data on interactions between household members, Ultra Wide Band (UWB) systems will be used. During 4 days, index cases and household members will wear a small wireless sensor that records continuously the identity of other sensors that are in close proximity. For each household, recording will be performed on 2 week days and 2 week-end days (Saturday and Sunday).

Proportion of transmissions in all household members over the study period (SAR) and 95% confidence intervals will be calculated at the end of follow-up for both probable and confirmed transmissions and described according to household size and index-case population type. Kaplan Meier survival analysis will be used to estimate the median time to (first) acquisition among household members and a Cox shared frailty-model to study variables associated with acquisition index-case and household members' potential exposures, household's characteristics, MDR-E abundance in index case-patients, intestinal microbiota diversity and composition). Additionally, a stochastic individual based model to capture the multifactorial processes involved in MDR-E transmission will developed. Several models of increasing complexity will be built in order to compare their likelihood given the acquisitions observed over time in the different households. The model will be integrated in an inference framework to analyse the data and estimate model parameters (eg transmission rates for the different routes). The inference techniques will involve bayesian statistics, probably Markov Chain Monte Carlo with data augmentation. The different models will be compared based on specific criterion, such as the Deviance Information Criterion (DIC). The parameterized model selected in the preceding step will be used to simulate and assess different strategies of control of MDR-E emergence and transmission to households.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Index patients

Adults MDR-E carriers.

No interventions assigned to this group

Household members

Adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Index patients

* adults (≥ 18 years)
* hospitalized in participating hospitals
* positive for MDR-E fecal carriage on routine screening during hospital stay
* with no documented MDR-E fecal carriage in the 12 months preceding current hospitalization
* regularly living with at least two additional household members who expressed their non-opposition to participate.
* planning to live in Ile de France for the next three months Household members
* adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion, and who expressed their non-opposition to participate.
* planning to live in Ile de France for the next three months

Exclusion Criteria

Lack of non-opposition to participate and to use clinical data

* Subject under legal protection (guardianship)
* Subject deprived of liberty under judicial constraint
* Subject undergoing psychiatric care
* Index member negative for MDR-E fecal carriage either before discharge (D-7 to D-2) or on day of discharge (D0)."
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kernéis Solen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bichat Hospital

Paris, Île-de-France Region, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kernéis Solen, MD, PhD

Role: CONTACT

+33 1 40 25 61 99

Armand-Lefevre Laurence, Pharm. D., PhD.

Role: CONTACT

+33 1 40 25 85 00

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Solen Kernéis, MD - PhD

Role: primary

33140256199

Claire Durand, MD

Role: backup

33686016726

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP220479

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sentinel Cohort REACT
NCT05780801 COMPLETED PHASE1